

Adamis Pharmaceuticals Corporation
11683 El Camino Real, Suite 300
San Diego, CA 92103

July 28, 2023

VIA EDGAR

Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549

**Re: Adamis Pharmaceuticals Corporation
Registration Statement on Form S-3 (No. 333-273233)
Filed on July 13, 2023**

Acceleration Request

**Requested Date: July 31, 2023
Requested Time: 5:30 P.M. Eastern Time**

To Whom it May Concern:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Adamis Pharmaceuticals Corporation (the "Company") hereby requests that the effective date of the above referenced registration statement, as amended (the "Registration Statement"), be accelerated to July 31, 2023, at 5:30 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Weintraub Tobin Chediak Coleman Grodin, law corporation, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Securities Act of 1933, as amended.

Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Weintraub Tobin, by calling Kevin Kelso at (916) 558-6110.

Very truly yours,

Adamis Pharmaceuticals Corporation

By: /s/ David J. Marguglio
David J. Marguglio
President
